Substituted benzoxazole and benzofuran compounds as pde7 inhibitors

A pharmaceutical composition comprising:

• a pharmaceutically acceptable carrier;
• and a compound of Formula (I), or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
• 5-chloro-2-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-ylmethyl]-7,8-dihydro-6H-spiro[[1,3]oxazolo[5,4-f]quinazoline-9,1′-cyclohexane]-7-one;
• 5-chloro-2-[(3-methoxy-3-methylazetidin-1-yl)methyl]-7,8-dihydro-6H-spiro[[1,3]oxazolo[5,4-f]quinazoline-9,1′-cyclohexane]-7-one;
• 5-chloro-2-{[3-(hydroxymethyl)pyrrolidin-1-yl]methyl}-7,8-dihydro-6H-spiro[[1,3]oxazolo[5,4-f]quinazoline-9,1′-cyclohexane]-7-one;
• and
• 5-chloro-2-({[2-(dimethylamino)ethyl](methyl)amino}methyl)-7,8-dihydro-6H-spiro[[1,3]oxazolo[5,4-f]quinazoline-9,1′-cyclohexane]-7-one.

A method of treating inhibiting or relieving a disorder or ameliorating a symptom of a disorder that includes having an aberrant or dysregulated signaling pathway mediated by PDE7 in a subject, the method comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof, selected from the group consisting of

• 5-chloro-2-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-ylmethyl]-7,8-dihydro-6H-spiro[[1,3]oxazolo[5,4-f]quinazoline-9,1′-cyclohexane]-7-one;
• 5-chloro-2-[(3-methoxy-3-methylazetidin-1-yl)methyl]-7,8-dihydro-6H-spiro[[1,3]oxazolo[5,4-f]quinazoline-9,1′-cyclohexane]-7-one;
• 5-chloro-2-{[3-(hydroxymethyl)pyrrolidin-1-yl]methyl}-7,8-dihydro-6H-spiro[[1,3]oxazolo[5,4-f]quinazoline-9,1′-cyclohexane]-7-one;
• and
• 5-chloro-2-({[2-(dimethylamino)ethyl](methyl)amino}methyl)-7,8-dihydro-6H-spiro[[1,3]oxazolo[5,4-f]quinazoline-9,1′-cyclohexane]-7-one.